

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beijing Airdoc Technology Co., Ltd.
北京鷹瞳科技發展股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2251)

**RESIGNATION OF DIRECTOR AND SUPERVISOR
PROPOSED APPOINTMENT OF DIRECTOR AND SUPERVISOR
AND**

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

**RESIGNATION AND PROPOSED APPOINTMENT OF DIRECTOR AND
SUPERVISOR**

This announcement is made by Beijing Airdoc Technology Co., Ltd. (the “**Company**”) pursuant to Rules 13.51(2) and 13.51(1) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Resignation of a Director and a Supervisor

The board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby announces that, (i) Mr. JIANG Bo (蔣波) (“**Mr. Jiang**”) has tendered his resignation as a non-executive Director with effect from the conclusion of the annual general meeting of the Company to be held on May 19, 2022 (the “**AGM**”), due to other work engagement; and (ii) Ms. ZHOU Wenjuan (周雯娟) (“**Ms. Zhou**”) has tendered her resignation as a supervisor of the Company with effect from the date of this announcement, due to other work engagement.

Mr. Jiang has confirmed that he has no disagreement with the Company and the Board. Ms. Zhou has confirmed that she has no disagreement with the Company, the Board and the board of supervisors of the Company (the “**Board of Supervisors**”). Both Mr. Jiang and Ms. Zhou have confirmed that there are no other matters relating to their resignation that need to be brought to the attention of the Stock Exchange and the shareholders of the Company.

The Board would like to take this opportunity to thank Mr. Jiang and Ms. Zhou for their valuable contributions to the Company.

Proposed Appointment of a Director and a Supervisor

The Board is pleased to announce that during its meeting held on March 17, 2022, it has resolved to nominate Mr. CHEN Xin (陳欣) (“**Mr. Chen**”) as a candidate for non-executive

Director of the first session of the Board and Dr. LUO Ting (羅婷) (“**Dr. Luo**”) as a candidate for supervisor of the first session of the Board of Supervisors, and has resolved to propose the appointment of Mr. Chen and Dr. Luo to the AGM for consideration and approval. The appointment of Mr. Chen as a non-executive director and the appointment of Dr. Luo as a supervisor will be effective upon the approval by the shareholders of the Company at the AGM.

The biographical details of Mr. Chen and Dr. Luo are as follows.

Mr. CHEN Xin (陳欣), aged 46. Mr. Chen has over 21 years of experience in finance and investment industries. From 1997 to 2000, Mr. Chen successively served as assistant trade service manager, assistant banking services manager and project finance executive in The Hongkong and Shanghai Banking Corporation Limited (HSBC Group). From 2002 to 2011, Mr. Chen successively served as associate and vice president of the corporate finance group of the investment banking division and executive director of the Asian Special Situations Group (ASSG) in Goldman Sachs (Asia) L.L.C. Mr. Chen served as head of China in Permira Advisors (Asia) Limited from 2011 to 2014, served as founding partner of Fides Capital Investors I, L.P. from 2014 to 2017, served as head of direct investment in CMBC Capital Holdings Limited from 2017 to 2018, served as a partner, managing director and head of private equity investment in Ally Bridge Group from 2018 to February 2020, served as the head of investment in Guangdong-Hong Kong-Macao Greater Bay Area and the president in Fosun Capital Flagship Fund from February 2020 to present, served as an independent non-executive director and a member of the audit committee of Fu Shou Yuan International Group Limited (SEHK code: 1448), from 21 January 2021 to present and served as non-executive director of Cosmo Lady (China) Holdings Company Limited (SEHK code: 2298) since February 2022.

Mr. Chen obtained a bachelor’s degree of arts in finance from Fudan University in 1997, a master’s degree in economics from The Hong Kong University of Science and Technology in 2000 and a master’s degree in business administration from The Yale School of Management, major in finance and business strategy, in 2002, respectively.

Dr. LUO Ting (羅婷), aged 47, is currently serving as a tenured associate professor at School of Economics and Management, Tsinghua University, and an independent director of (i) Digital China Information Service Company Ltd. (神州數碼信息服務股份有限公司), a company whose shares listed on the Shenzhen Stock Exchange (stock code: 000555); (ii) IAT Automobile Technology Co., Ltd. (阿爾特汽車技術股份有限公司), a company whose shares listed on the Shenzhen Stock Exchange (stock code: 300825); (iii) Beijing Thunisoft Co.,Ltd. (北京華宇軟體股份有限公司), a company whose shares listed on the Shenzhen Stock Exchange (stock code: 300271) and (iv) Beijing Sanyuan Foods Co., Ltd. (北京三元食品股份有限公司), a company whose shares listed on the Shanghai Stock Exchange (stock code: 600429).

Dr. Luo served as an assistant professor and associate professor at School of Economics and Management, Tsinghua University from September 2007 to November 2016. Prior to that, she served as a financial analyst in China Life Insurance Company Limited (中國人壽保險股份有限公司) from 1997 to 2002. Dr. Luo participated in teaching and research projects covering topics of accounting and finance. Dr. Luo was certified as a certified public accountant by the Institute of Certified Public Accountants of the People's Republic of China.

Dr. Luo obtained a bachelor's degree in business management from Peking University and a doctor of philosophy in accounting from University of Wisconsin-Madison in the United States in 1997 and 2007, respectively.

The terms of office of Mr. Chen shall commence from the date of approval at the AGM until the expiry of the term of the first session of the Board. He shall be eligible for re-election upon the expiry of his terms of office. The Company will enter into a three-year service contract with Mr. Chen upon approval at the AGM. Mr. Chen will not receive remuneration from the Company during his term of office.

The term of office of Dr. Luo shall commence from the date of approval at the AGM until the expiry of the term of the first session of the Board of Supervisors. She shall be eligible for re-election upon the expiry of her term of office. The Company will enter into a three-year service contract with Dr. Luo upon approval at the AGM. Dr. Luo will receive an annual fee of RMB100,000 (tax included) from the Company.

Save as disclosed above, Mr. Chen and Dr. Luo did not hold any directorships in any listed companies in the past three years prior to the date of this announcement, did not hold any positions in the Company or any of its subsidiaries, and did not have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company. As of the date of this announcement, Mr. Chen and Dr. Luo did not have any interest in the securities of the Company (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)). Mr. Chen and Dr. Luo have not been subject to any penalty or punishment imposed by the China Securities Regulatory Commission or any other relevant authorities or stock exchanges. Save as disclosed above, the Board is not aware of other information on the proposed appointment of Mr. Chen and Dr. Luo which shall be disclosed pursuant to the requirements set out in Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company.

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

During its meeting held on March 17, 2022, the Board has also resolved to approve the proposal of making housekeeping amendments to the articles of association of the Company (“**Articles of Association**”), the details of which are set out below:

No.	Article before amendments	Article after amendments
1.	<p>Article 3</p> <p>The Company won the approval from China Securities Regulatory Commission (hereafter referred to as the “CSRC”) to offer the overseas listed foreign shares of 31,165,300 on August 26, 2021 (hereafter referred to as the “H-shares”), 3,666,918 unlisted foreign shares were converted to overseas listed foreign shares and the H-shares were listed on the Stock Exchange of Hong Kong Limited on November 5, 2021.</p>	<p>Article 3</p> <p>The Company won the approval from China Securities Regulatory Commission (hereafter referred to as the “CSRC”) to offer the overseas listed foreign shares of <u>22,267,200</u>31,165,300 on August 26, 2021 (hereafter referred to as the “H-shares”), 3,666,918 unlisted foreign shares were converted to overseas listed foreign shares and the H-shares were listed on the Stock Exchange of Hong Kong Limited on November 5, 2021.</p>
2.	<p>Article 6</p> <p>The registered capital of the Company is RMB112,466,113.</p>	<p>Article 6</p> <p>The registered capital of the Company is RMB<u>103,568,013</u>112,466,113.</p>

3.	<p>Article 23</p> <p>The Company has made an initial public offering of 31,165,300 overseas listed foreign shares upon the approval from the securities regulator of the State Council. 3,666,918 unlisted foreign shares of the Company were converted to overseas listed foreign shares. The share capital structure of the Company on the listing date is demonstrated as follows after the aforesaid H shares are issued (provided that the over-allotment options are not exercised): 112,466,113 ordinary shares, including 77,633,895 domestic shares and 34,832,218 H shares. The registered capital of the Company is RMB1,124,661,130,000 on the listing date.</p>	<p>Article 23</p> <p>The Company has made an initial public offering of <u>22,267,200</u> 31,165,300 overseas listed foreign shares upon the approval from the securities regulator of the State Council., 3,666,918 unlisted foreign shares of the Company were converted to overseas listed foreign shares. The share capital structure of the Company on the listing date is demonstrated as follows after the aforesaid H shares are issued (provided that the over-allotment options are not exercised): <u>103,568,013</u> 112,466,113 ordinary shares, including 77,633,895 domestic shares and <u>25,934,118</u> 34,832,218 H shares. The registered capital of the Company is RMB<u>103,568,013</u> 1,124,661,130,000 on the listing date.</p>
4.	<p>Article 50</p> <p>No changes in the shareholders' register due to the transfer of shares may be made within 30 days before the date of a general meeting or within 5 days before the record date for the Company's distribution of dividends.</p> <p>...</p>	<p>Article 50</p> <p>No changes in the shareholders' register due to the transfer of shares may be made within 30 <u>5</u> days before the date of a general meeting or within 5 days before the record date for the Company's distribution of dividends.</p> <p>...</p>

<p>5.</p>	<p>Article 67 The general meeting is the organ of authority of the Company, which exercises its following functions and powers in accordance with the law:</p> <p>...</p> <p>(XIV) examining purchase or sale of material assets of the Company that exceed 30% of the Company's total audited assets in the latest period within one year;</p> <p>...</p>	<p>Article 67 The general meeting is the organ of authority of the Company, which exercises its following functions and powers in accordance with the law:</p> <p>...</p> <p>(XIV) examining purchase or sale of material assets of the Company that exceed 30 <u>25</u>% of the Company's total audited assets in the latest period within one year;</p> <p>...</p>
<p>6.</p>	<p>Article 101 The following matters shall be approved by ordinary resolutions at a general meeting:</p> <p>...</p> <p>(IV) annual financial budgets, final accounts, balance sheets, income statements and other financial statements of the Company;</p> <p>(V) The Company's annual report;</p> <p>(VI) other matters than those that should be passed by special resolutions pursuant to the laws, administrative regulations, regulatory rules of the place where the Company's shares are listed or the Articles of Association</p>	<p>Article 101 The following matters shall be approved by ordinary resolutions at a general meeting:</p> <p>...</p> <p>(IV) annual financial budgets, <u>and</u> final accounts, balance sheets, income statements and other financial statements of the Company;</p> <p>(V) The Company's annual report;</p> <p><u>(V</u> VI) other matters than those that should be passed by special resolutions pursuant to the laws, administrative regulations, regulatory rules of the place where the Company's shares are listed or the Articles of Association</p>

<p>7.</p>	<p>Article 102 The following matters shall be approved by special resolutions at a general meeting:</p> <p>...</p> <p>(V) the Company's acquisition or disposal of major assets within one year with the transaction amount exceeding 30% of the latest audited total assets of the Company;</p> <p>...</p>	<p>Article 102 The following matters shall be approved by special resolutions at a general meeting:</p> <p>...</p> <p>(V) the Company's acquisition or disposal of major assets within one year with the transaction amount exceeding 30 <u>25</u>% of the latest audited total assets of the Company;</p> <p>...</p>
<p>8.</p>	<p>Article 126 The Board is responsible to the general meeting and exercises the following functions and powers:</p> <p>...</p> <p>(XVI) to manage the information disclosure of the Company according to laws and regulations, the Hong Kong Listing Rules and the internal rules and regulations of the Company;</p> <p>(XVII) to decide on other major affairs of the Company, except for the matters that shall be resolved by the general meeting as specified in the Company Law and the Articles of Association;</p> <p>(XVIII) Other functions and powers set out in and granted by the relevant laws, administrative regulations, departmental rules and Articles of Association.</p>	<p>Article 126 The Board is responsible to the general meeting and exercises the following functions and powers:</p> <p>...</p> <p><u>(XVI) to review, supervise, evaluate, manage and approve the material sustainable development matters;</u></p> <p>(XVII) (XVI) to manage the information disclosure of the Company according to laws and regulations, the Hong Kong Listing Rules and the internal rules and regulations of the Company;</p>

		<p>(XVIII XVII) to decide on other major affairs of the Company, except for the matters that shall be resolved by the general meeting as specified in the Company Law and the Articles of Association;</p> <p>(XIX XVIII) Other functions and powers set out in and granted by the relevant laws, administrative regulations, departmental rules and Articles of Association.</p>
--	--	---

Save for the above amendments to the Articles of Association, other provisions of the Articles of Association remain unchanged.

The proposed amendments to the Articles of Association will come into force upon approval at the AGM. A circular containing details of the proposed amendments to the Articles of Association will be despatched to the shareholders of the Company in due course.

By order of the Board
Beijing Airdoc Technology Co., Ltd.
Mr. ZHANG Dalei
Chairman of the Board

Hong Kong, March 17, 2022

As of the date of this announcement, the Board comprises Mr. ZHANG Dalei, Mr. GAO Fei, Dr. CHEN Yuzhong and Mr. CHEN Hailong as executive Directors; Mr. JIANG Bo and Ms. WANG Mi as non-executive Directors; and Mr. NG Kong Ping Albert, Mr. WU Yangfeng and Mr. HUANG Yanlin as independent non-executive Directors.